查詢結果分析
來源資料
相關文獻
- Autoimmune Manifestations in Patients with Primary Immunodeficiency
- Clinical Outcome After Emergency Surgery for Ulcerative Colitis
- 潰瘍性結腸炎與克隆氏症
- The Correlation of Clinical Activities to Serum Interleukin-6 Concentration in Patients with Ulcerative Colitis
- 發炎性腸道疾病之營養支持
- 克隆氏症
- 潰瘍性結腸炎的中醫治療病例報告
- Ulcerative Colitis Associated with Polymyositis, Polyarthritis, and Hepatitis: Response to Partial Colectomy
- 安腸克錠(Asacol Tablets)與Salazopyrin Tablets在治療潰瘍性結腸炎之臨床交叉比較試驗
- 潰瘍性結腸炎的藥物治療
頁籤選單縮合
題名 | A Comparison of the Efficacy and Safety of Balsalazide (Basazyde[feb9]) and Mesalamine (Asacol[feb9]) for the Treatment of Acute Exacerbation of Ulcerative Colitis=比較使用Balsalazide (Basazyde) 和Mesalamine (Asacol) 來治療急性惡化潰瘍性結腸炎的效果和安全性 |
---|---|
作者姓名(中文) | 陳建彰; 許自齊; 王輝明; 金台明; 吳登強; 陳自諒; 陳啟益; 高愛文; | 書刊名 | 中華民國大腸直腸外科醫學會雜誌 |
卷期 | 17:3 民95.09 |
頁次 | 頁63-70 |
分類號 | 416.245 |
關鍵詞 | 潰瘍性結腸炎; Balsalazide (Basazyde[feb9]); Mesalamine (Asacol[feb9]); Ulcerative colitis; |
語文 | 英文(English) |
中文摘要 | 目的:這是一個隨機、多所醫學中心參與、雙盲、雙仿的研究,來評估在八個星期中使用Balsalazide (Basazyde) 和Mesalamine (Asacol) 來治療急性惡化潰瘍性結腸炎的效果和安全性。 方法:參與治療的對象是有急性惡化潰瘍性結腸炎的病患,而且經乙狀結腸鏡檢查有二到四級的徵狀。病患隨機接受Balsalazide (750mg/cap,3# tid) 或 Mesalamine (400mg/tab,2# tid) 的治療。總共有52位病患加入這個研究,其中有40位完成八個星期的治療。功效和安全性在八個星期的治療之後被評估。 結果:在Mesalamine組中17位有8位 (47.1%),在Balsalazide組中23位有10位 (43.5%)病人的症狀完全解除。經乙狀結腸鏡觀察的改善程度在Balsalazide組 (82.35% ) 顯著的比Mesalamine組 (47.83%) 好。在Balsalazide組24位病人中有17位 (70.8%),而在Mesalamine組28位病人中有18位 (64.3%) 發生不良反應的事件。在臨床上例行的實驗室檢查和生命徵象在兩組都沒有顯著的變化。 結論:這個研究證實在八個星期中每天使用6.75公克Balsalazide來治療急性惡化潰瘍性結腸炎是安全的,可被接受的,而且是有效的。因此證明用Balsalazide來治療急性惡化潰瘍性結腸炎是有效的。 |
英文摘要 | Purpose: This is a randomized, multi-center, double-dummy, and active-controlled study to evaluate the efficacy and safety of balsalazide as compared to mesalamine for a treatment period of eight weeks in patients with acute exacerbation of ulcerative colitis. Methods: Subjects with acute exacerbation of ulcerative colitis and had symptomatic grade 2~4 ulcerative colitis after being checked by sigmoidoscopic examination were recruited for the study. Subjects were randomized to received balsalazide (750 mg/cap, 3# tid) and mesalamine (400 mg/tab, 2# tid). Fifty-two subjects were enrolled into the study, forty of them completed eight weeks treatment. Efficacy and safety were evaluated after eight weeks treatment. Results: Complete remission occurred in 8 of 17 (47.1%) patients in the balsalazide group and 10 of 23 (43.5%) patients in the mesalamine group. Sigmoidoscopic improvement is more significant in the balsalazide group (82.35%) than mesalamine group (47.83%). Adverse event was experienced in 17 of 24 patients (70.8%) in the balsalazide group and 18 of 28 patients (64.3%) in the mesalamine group. There were no clinically significant changes in routine laboratory assessments and vital signs in either treatment groups. Conclusion: This study confirmed that 8 weeks of treatment with 6.75g daily of balsalazide is safe, well tolerated, and effective for acute ulcerative colitis. Balsalazide is therefore proven to be an effective treatment in the management of ulcerative colitis. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。